Page last updated: 2024-10-21

ethylisopropylamiloride and Tuberous Sclerosis

ethylisopropylamiloride has been researched along with Tuberous Sclerosis in 1 studies

ethylisopropylamiloride: structure in first source
ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.

Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Filippakis, H1
Belaid, A1
Siroky, B1
Wu, C1
Alesi, N1
Hougard, T1
Nijmeh, J1
Lam, HC1
Henske, EP1

Other Studies

1 other study available for ethylisopropylamiloride and Tuberous Sclerosis

ArticleYear
Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
    Scientific reports, 2018, 09-21, Volume: 8, Issue:1

    Topics: Amiloride; Animals; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; Cell Line; Cell Prolifer

2018